ライフサイエンスコーパス: hepatitis D

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 tis B, as therapy in 5 patients with chronic hepatitis D.

2 ant women, in children, and in patients with hepatitis D and C virus coinfection.

3 y was shown to be effective in patients with hepatitis D and ribavirin provides no additional benefit

4 hepatitis B e antigen [HBeAg] negative, anti-hepatitis D antigen [HDAg] positive, and HDV RNA positiv

5 s of diversifying selective pressures on the hepatitis D antigen gene (HDAg).

6 stigate the efficacy of entecavir in chronic hepatitis D (CHD).

7 gests that acute HCV infection, unrecognized hepatitis D infection, and hepatitis E may all represent

8 ring acute flares of disease, and with acute hepatitis D superinfection.

9 The hepatitis D virion is composed of a coat of HBV envelope

10 Hepatitis D virus (also known as hepatitis delta virus)

11 activity of vanitaracin A was observed with hepatitis D virus (HDV) but not hepatitis C virus.

12 ron alfa-2a in patients with chronic HBV and hepatitis D virus (HDV) co-infection.

13 s with the human hepatitis B virus (HBV) and hepatitis D virus (HDV) depend on species-specific host

14 Hepatitis D virus (HDV) infection affects 15-20 million

15 appears to be an autonomous, or "isolated," hepatitis D virus (HDV) infection following the transpla

16 The emergence of hepatitis D virus (HDV) infection in the era of widespre

17 The role of hepatitis B virus (HBV) and hepatitis D virus (HDV) infection was investigated as th

18 and treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, we still do not comp

19 Superinfection with hepatitis D virus (HDV) may increase the risk for hepati

20 Hepatitis D virus (HDV) particles pseudotyped with HBV a

21 Hepatitis D virus (HDV) requires hepatitis B surface ant

22 As previously shown by using the hepatitis D virus (HDV) system, recombinant HBV-HDV part

23 ch inhibited the process of entry of HBV and hepatitis D virus (HDV).

24 We aimed to establish the prevalence of hepatitis D virus among HBsAg-positive populations in su

25 n binding and in vitro infection assays with hepatitis D virus as a surrogate for HBV, we established

26 tions if HBV recurrence occurs (i.e., HIV or hepatitis D virus coinfection, preexisting drug resistan

27 The odds ratio for anti-hepatitis D virus detection among HBsAg-positive patient

28 TION: Findings suggest localised clusters of hepatitis D virus endemicity across sub-Saharan Africa.

29 a, where HBsAg prevalence is higher than 8%, hepatitis D virus might represent an important additive

30 Hepatitis D virus particles pseudotyped with surface pro

31 We systematically reviewed studies of hepatitis D virus prevalence among HBsAg-positive popula

32 y, only eight of which included detection of hepatitis D virus RNA among anti-hepatitis D virus serop

33 etection of hepatitis D virus RNA among anti-hepatitis D virus seropositive participants.

34 ects model to calculate a pooled estimate of hepatitis D virus seroprevalence.

35 dies should aim to define the reliability of hepatitis D virus testing methods, identify risk factors

36 In west Africa, the pooled seroprevalence of hepatitis D virus was 7.33% (95% CI 3.55-12.20) in gener

37 ) positive, human immunodeficiency virus and hepatitis D virus-negative patients with pretransplant H

38 , the countries therein, and permutations of hepatitis D virus.

39 The receptor that allows hepatitis B and hepatitis D viruses to enter human liver cells has been

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。